Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Assets (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Assets readings, the most recent being $436.8 million for Q1 2026.

  • Quarterly Assets rose 79.84% to $436.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $436.8 million through Mar 2026, up 79.84% year-over-year, with the annual reading at $408.9 million for FY2025, 49.15% up from the prior year.
  • Assets hit $436.8 million in Q1 2026 for Oric Pharmaceuticals, up from $408.9 million in the prior quarter.
  • Across five years, Assets topped out at $436.8 million in Q1 2026 and bottomed at $226.6 million in Q1 2023.
  • Average Assets over 5 years is $305.1 million, with a median of $275.1 million recorded in 2022.
  • The largest annual shift saw Assets plummeted 30.77% in 2025 before it skyrocketed 79.84% in 2026.
  • Oric Pharmaceuticals' Assets stood at $247.2 million in 2022, then increased by 1.95% to $252.0 million in 2023, then rose by 8.78% to $274.1 million in 2024, then surged by 49.15% to $408.9 million in 2025, then increased by 6.82% to $436.8 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Assets are $436.8 million (Q1 2026), $408.9 million (Q4 2025), and $431.2 million (Q3 2025).